{"address1": "9804 Medical Center Drive", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "240 552 8181", "website": "https://www.regenxbio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 353, "companyOfficers": [{"maxAge": 1, "name": "Mr. Curran M. Simpson M.S.", "age": 62, "title": "President, CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 698604, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Olivier  Danos Ph.D.", "age": 66, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 778851, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stephen  Pakola M.D.", "age": 55, "title": "Executive VP & Chief Medical Officer", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 674050, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mitchell  Chan M.B.A.", "age": 43, "title": "Executive VP & CFO", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Craig  Malzahn", "title": "Executive Vice President, Product Development & CTO", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick J. Christmas II, J.D.", "age": 53, "title": "Executive VP & Chief Legal Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 1111209, "exercisedValue": 1294231, "unexercisedValue": 140919}, {"maxAge": 1, "name": "Ms. Shiva G. Fritsch", "title": "Chief Communications & People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ram  Palanki Pharm.D.", "age": 47, "title": "Executive VP of Commercial Strategy & Operations", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 7.15, "open": 7.18, "dayLow": 6.609, "dayHigh": 7.18, "regularMarketPreviousClose": 7.15, "regularMarketOpen": 7.18, "regularMarketDayLow": 6.609, "regularMarketDayHigh": 7.18, "payoutRatio": 0.0, "beta": 1.353, "forwardPE": -6.259259, "volume": 943653, "regularMarketVolume": 943653, "averageVolume": 969088, "averageVolume10days": 1081620, "averageDailyVolume10Day": 1081620, "bid": 6.73, "ask": 6.79, "bidSize": 2, "askSize": 1, "marketCap": 338582048, "fiftyTwoWeekLow": 5.62, "fiftyTwoWeekHigh": 20.77, "priceToSalesTrailing12Months": 4.063245, "fiftyDayAverage": 7.3826, "twoHundredDayAverage": 9.83675, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 245615296, "profitMargins": -2.7254, "floatShares": 41159286, "sharesOutstanding": 50086100, "sharesShort": 6048547, "sharesShortPriorMonth": 6168873, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.120799996, "heldPercentInsiders": 0.07349, "heldPercentInstitutions": 0.87485003, "shortRatio": 7.14, "shortPercentOfFloat": 0.1574, "impliedSharesOutstanding": 50086100, "bookValue": 5.24, "priceToBook": 1.2900765, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -227102000, "trailingEps": -4.59, "forwardEps": -1.08, "enterpriseToRevenue": 2.948, "enterpriseToEbitda": -1.142, "52WeekChange": -0.66617286, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 6.76, "targetHighPrice": 52.0, "targetLowPrice": 14.0, "targetMeanPrice": 33.08333, "targetMedianPrice": 32.0, "recommendationMean": 1.58333, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 234687008, "totalCashPerShare": 4.686, "ebitda": -215030000, "totalDebt": 141720000, "quickRatio": 2.593, "currentRatio": 2.694, "totalRevenue": 83328000, "debtToEquity": 54.581, "revenuePerShare": 1.683, "returnOnAssets": -0.27795, "returnOnEquity": -0.79490995, "grossProfits": 49761000, "freeCashflow": -95453000, "operatingCashflow": -173124992, "revenueGrowth": -0.045, "grossMargins": 0.59717, "ebitdaMargins": -2.5805302, "operatingMargins": -2.42142, "financialCurrency": "USD", "symbol": "RGNX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1442496600000, "preMarketChange": -0.07000017, "preMarketChangePercent": -1.0355054, "preMarketPrice": 6.69, "marketState": "PRE", "regularMarketChangePercent": -5.4545436, "regularMarketPrice": 6.76, "shortName": "REGENXBIO Inc.", "longName": "REGENXBIO Inc.", "regularMarketChange": -0.38999987, "regularMarketDayRange": "6.609 - 7.18", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 969088, "fiftyTwoWeekLowChange": 1.1400003, "fiftyTwoWeekLowChangePercent": 0.20284703, "fiftyTwoWeekRange": "5.62 - 20.77", "fiftyTwoWeekHighChange": -14.01, "fiftyTwoWeekHighChangePercent": -0.67453057, "fiftyTwoWeekChangePercent": -66.61729, "earningsTimestamp": 1741896306, "earningsTimestampStart": 1746529140, "earningsTimestampEnd": 1747051200, "earningsCallTimestampStart": 1741897800, "earningsCallTimestampEnd": 1741897800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -4.59, "epsForward": -1.08, "epsCurrentYear": -0.9821, "priceEpsCurrentYear": -6.8832097, "fiftyDayAverageChange": -0.6225996, "fiftyDayAverageChangePercent": -0.08433338, "twoHundredDayAverageChange": -3.0767498, "twoHundredDayAverageChangePercent": -0.31278113, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "corporateActions": [], "preMarketTime": 1743596626, "regularMarketTime": 1743537601, "exchange": "NMS", "messageBoardId": "finmb_130641748", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "REGENXBIO", "trailingPegRatio": null}